Inventiva S.A. and Hepalys Pharma Inc. have entered into an exclusive licensing agreement to develop and commercialize Inventiva's proprietary drug candidate lanifibranor for the treatment of non-alcoholic steatohepatitis (NASH) in Japan and South Korea. Under the terms of this licensing agreement, Inventiva will receive a $10 million upfront payment, and is eligible to receive up to $231 million in milestone payments if certain clinical, regulatory and commercial conditions are met.
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
3.52 EUR | +2.33% | +7.98% | -14.04% |
May. 13 | Inventiva: additional Phase 2 results in NASH | CF |
Apr. 22 | Inventiva: UBS Group falls below 5% threshold | CF |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.04% | 194M | |
+5.33% | 111B | |
+12.11% | 106B | |
-12.56% | 22.24B | |
-3.67% | 21.25B | |
-6.03% | 18.97B | |
-35.21% | 18.52B | |
-10.86% | 16.81B | |
+37.57% | 12.54B | |
-26.24% | 8.09B |
- Stock Market
- Equities
- IVA Stock
- News Inventiva
- Inventiva S.A. and Hepys Pharma, Inc. Announce Exclusive Licensing Agreement to Develop and Commercialize Lanifibranor in Japan and South Korea